ASCO

Research by D. Romanus and colleagues in colon cancer provides new insights.
Cancer Weekly; 11/17/2009; 1100 words; ...of quality metrics jointly developed by ASCO and NCCN in 2007. Adherence rates were...with NCCN colorectal cancer guidelines and ASCO/NCCN quality measures were generally...with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: An NCCN Institutional...

Ym Biosciences Reports Positive Nimotuzumab Four-year Survival Data Presented At Astro 2009.(Clinical report)
Cancer Weekly; 11/17/2009; 1534 words; ...data were a follow-up to 30-month survival data presented at ASCO 2009 and demonstrate that the benefit of adding nimotuzumab to...describing 30-month data from this trial was presented at the 2009 ASCO Annual Meeting and is entitled: "A Phase IIb 4-arm open...

Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover.
PR Newswire; 11/16/2009; 1148 words; ...presented at the American Society of Oncology Annual Meeting (ASCO) earlier this year, Oncothyreon has made the decision to move...and Chief Executive Officer of Oncothyreon. "As reported at ASCO, we have also had several patients with prolonged stable disease...

Semafore Pharmaceuticals Announces Phase I Data Presentation Highlighting Novel PI3K Pathway Inhibitor at 51st ASH Annual Meeting.
Business Wire; 11/16/2009; 1232 words; ...clinical trial of SF1126 in patients with solid tumors recently presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated selective inhibition of the PI3K pathway in tumor tissue but not in normal skin tissue. Notably...

Genta Announces Third Quarter 2009 Financial Results and Restructuring to Focus on Core Oncology Initiatives.(Financial report)
Business Wire; 11/16/2009; 3149 words; ...these data will be submitted for presentation to the June 2010 annual meeting of the American Society of Clinical Oncology (ASCO). Pending FDA agreement, The Company plans to initiate 4 new clinical trials with tesetaxel, as follows: * Dose-ranging...